Stay updated on Nivolumab Safety in Chinese Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Safety in Chinese Solid Tumors Clinical Trial page.

Latest updates to the Nivolumab Safety in Chinese Solid Tumors Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.4.3 released, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows Revision: v3.4.2. The previously displayed government funding notice and the older Revision: v3.4.1 banner were removed.SummaryDifference0.4%

- Check41 days agoChange DetectedA notice about a lapse in government funding was added, informing users about potential delays and directing to cc.nih.gov and opm.gov for status updates. The page shows a new revision identifier, v3.4.1, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedMinor UI/content updates: a glossary toggle is now shown and the QC criteria label capitalization was adjusted to 'Met QC Criteria'. The revision is updated to v3.4.0 and the No FEAR Act Data notice was added.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.1%

- Check84 days agoChange DetectedThe page now includes a dedicated Locations section with Guangdong and Zhejiang as study sites, and the revision label has been updated to v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Nivolumab Safety in Chinese Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Safety in Chinese Solid Tumors Clinical Trial page.